Association Between Variants in Calcineurin Inhibitor Pharmacokinetic and Pharmacodynamic Genes and Renal Dysfunction in Adult Heart Transplant Recipients

Kris Oreschak¹, Laura M. Saba¹, Nicholas Rafaels², Amrut V. Ambardekar³, Kimberly M. Deininger¹, Robert L. Page II⁴, JoAnn Lindenfeld⁵ and Christina L. Aquilante¹*

¹Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, United States, ²Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States, ³Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, United States, ⁴Division of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmacetical Sciences, Aurora, CO, United States, ⁵Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, United States

Background: The goal of the study was to assess the relationship between single nucleotide variants (SNVs) in calcineurin inhibitor (CNI) pharmacokinetic and pharmacodynamic genes and renal dysfunction in adult heart transplant (HTx) recipients.

Methods: This retrospective analysis included N = 192 patients receiving a CNI at 1-year post-HTx. Using a candidate gene approach, 93 SNVs in eight pharmacokinetic and 35 pharmacodynamic genes were chosen for investigation. The primary outcome was renal dysfunction 1-year after HTx, defined as an estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m².

Results: Renal dysfunction was present in 28.6% of patients 1-year after HTx. Two SNVs [transforming growth factor beta 1 (TGFB1) rs4803455 C > A and phospholipase C beta 1 (PLCB1) rs170549 G > A] were significantly associated with renal dysfunction after accounting for a false discovery rate (FDR) of 20%. In a multiple-SNV adjusted model, variant A allele carriers of TGFB1 rs4803455 had lower odds of renal dysfunction compared to C/C homozygotes [odds ratio (OR) 0.28, 95% CI 0.12–0.62; p = 0.002], whereas PLCB1 rs170549 variant A allele carriers had higher odds of the primary outcome vs. patients with the G/G genotype (OR 2.66, 95% CI 1.21–5.84, p = 0.015).

Conclusion: Our data suggest that genetic variation in TGFB1 and PLCB1 may contribute to the occurrence of renal dysfunction in HTx recipients receiving CNIs. Pharmacogenetic markers, such as TGFB1 rs4803455 and PLCB1 rs170549, could help identify patients at increased risk of CNI-associated renal dysfunction following HTx, potentially allowing clinicians to provide more precise and personalized care to this population.

Keywords: renal dysfunction, estimated glomerular filtration rate, heart transplant, pharmacogenetics, pharmacogenomics, calcineurin inhibitor, single nucleotide variant
INTRODUCTION

Renal dysfunction is a major challenge following heart transplantation, with over 50% of patients experiencing some degree of renal impairment at 1-year post-transplant (Hamour et al., 2009; Navarro-Manchon et al., 2010). Renal dysfunction is associated with significant morbidity and a 4-fold increase in the risk of mortality in heart transplant recipients (van Gelder et al., 1998; Ojo et al., 2003; Alba et al., 2016; Kolsrud et al., 2018). The development of renal dysfunction is multifactorial, with contributing factors such as older age at transplant, other comorbidities (e.g., hypertension and diabetes mellitus), and long-term use of nephrotoxic drugs such as calcineurin inhibitors (CNIs; Wilkinson and Cohen, 1999; Ojo, 2007).

Calcineurin inhibitors remain the cornerstone of maintenance immunosuppressant therapy following heart transplantation, with 98% of patients receiving a CNI, most commonly tacrolimus, at 1-year post-transplant (Khush et al., 2019). Although excellent at preventing rejection, CNIs are associated with the development of chronic renal dysfunction, the exact mechanism of which is unknown. Importantly, systemic CNI exposure is not predictive of renal impairment, as renal dysfunction often occurs despite CNI trough blood levels being within goal range (van Gelder et al., 1998; Wilkinson and Cohen, 1999).

The field of pharmacogenetics seeks to characterize the impact of genetic variation, including single nucleotide variants (SNVs), on drug disposition, response, and adverse effects (Rodén et al., 2019). To date, only two pharmacogenetic studies have comprehensively investigated the association between SNVs and renal function in heart transplant recipients; however, CNI prescribing patterns in those studies do not reflect contemporary clinical practice, with only 21–36% of patients on tacrolimus therapy (Lachance et al., 2012; Asleh et al., 2018). Given the deleterious consequences of renal dysfunction after heart transplant and the contribution of CNIs to its development, there is a critical need to identify novel, patient-specific factors that increase the risk of this adverse effect. As such, the goal of this study was to evaluate the association between SNVs in key CNI pharmacokinetic and pharmacodynamic genes and renal dysfunction in heart transplant recipients taking CNIs at 1-year post-transplant.

MATERIALS AND METHODS

Study Population

The data for this retrospective cohort study were obtained from heart transplant patients who had participated in a parent pharmacogenomic study at the University of Colorado. The overarching goal of the parent study was to assess the association between SNVs and renal dysfunction in patients receiving CNIs in the first 5 years post-heart transplant. Patients were included in the parent study if they had received a heart-only transplant, were at least 18 years old at the time of transplant, and were prescribed a CNI post-transplant. Patients were excluded if they underwent multi-organ transplant or did not provide informed consent. In total, 253 adult heart transplant recipients were enrolled in the parent study at routine clinic visits, where a mouthwash or blood sample was collected for genetic analysis. Demographic and clinical data were retrospectively collected from participants’ medical records at the following time points: pre-transplant, transplant discharge, 6 months post-transplant, and annually from 1 to 5-years post-transplant. The parent study was approved by the Colorado Multiple Institutional Review Board and all participants provided written, informed consent.

Here, we describe analyses for the 1-year post-transplant time point. Parent study participants were included in these analyses if they received a CNI at the 1-year post-transplant clinical visit and had at least one estimated glomerular filtration rate (eGFR) measurement available in their medical records in the 3 months prior to transplant and at 1-year after transplantation (±2 months). Participants were excluded if they did not receive a CNI at the 1-year post-transplant clinical visit or if eGFR measurements were unavailable. Those transplanted at hospitals other than the University of Colorado were included if relevant clinical data were available in their medical records. The number of participants from the parent study who met eligibility criteria for the 1-year analysis was N = 192.

### Study Outcomes

The primary outcome of the study was renal dysfunction (yes/no), defined as an eGFR <45 ml/min/1.73 m² [i.e., grade 3B or worse per the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines] calculated using the Modification of Diet in Renal Disease (MDRD) formula, at 1-year post-transplant (National Kidney Foundation, 2002; Zalawadiya et al., 2017). The single eGFR measurement closest to the 1-year transplant anniversary (±2 months) was used to assess renal dysfunction. The secondary outcomes were the continuous measurements of eGFR 1-year after transplantation and change in eGFR from pre-transplant to 1-year post-transplant. CNI exposure was defined as being prescribed either cyclosporine or tacrolimus at the 1-year post-transplant clinical visit.

### Genotyping, Quality Control, and Imputation

Genomic DNA was isolated from either buccal cells in mouthwash samples or leukocytes in whole blood using a commercially available kit (QIAamp® DNA Mini Kit; Qiagen, Valencia, CA, United States). Genotyping was performed on a customized version of the Illumina® Expanded Multi-Ethnic Global Array (CU-MEGA®; Illumina, 2015). The CU-MEGA® contains over 2 million genetic variants, including over 20,000 drug metabolism and excretion markers, and incorporates content from Phase 3 of the 1,000 Genomes Project, the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA), and Population Architecture using Genomics and Epidemiology (PAGE; Mattise et al., 2011; 1000 Genomes Project Consortium, 2015; Mathias et al., 2016).

Genotype quality control was performed using PLINK v1.90 (Chang et al., 2015). Patients with array-wide call rates <90% were excluded from the analysis. Next, we selected a set of high-quality SNVs to determine heterozygosity, relatedness, and
principal components (PCs). High-quality SNVs were defined as having Hardy-Weinberg equilibrium values of $p > 1 \times 10^{-6}$, call rates $>95\%$, and minor allele frequencies $>1\%$. Patients with excessively high heterozygosity rates (i.e., $>3$ SD above the mean) and one sibling from a pair of related samples (defined as a pairwise identity by descent $>0.185$) were excluded from the analysis. Using the scree test, the top four PCs were selected for inclusion in adjusted models based on the "elbow" of the scree plot (Supplementary Figure S1). Variants not present on the CU-MEGA3 were imputed using the Michigan Imputation server (Das et al., 2016). Imputation was performed using Minimac4, with the Haplotype Reference Consortium version r1.1 2016 serving as the reference panel (McCarthy et al., 2016). SNVs with imputation values of $r^2 > 0.6$, minor allele frequencies $>5\%$, and Hardy-Weinberg equilibrium values of $p > 1 \times 10^{-6}$ in Americans of European ancestry were considered for analysis.

Following quality control and imputation procedures, we employed a candidate gene approach, whereby we selected SNVs in CNI pharmacokinetic and pharmacodynamic genes. Candidate genes were chosen based on the following criteria: (1) genes involved in CNI clinical pharmacology and renal pathophysiology; (2) genes previously associated with renal function in transplant populations; and (3) significant predictors of non-transplant chronic kidney disease in genome wide association studies (Baan et al., 2000; Lacha et al., 2001; van de Wetering et al., 2006; Kottgen et al., 2008; Smith et al., 2008; Jacobson et al., 2012; Lachance et al., 2012). Within these genes, we chose SNVs based on functional or clinical significance, annotation in pharmacogenomic databases, and/or HapMap tagging variants. In total, 93 SNVs were evaluated – 22 SNVs in eight CNI pharmacokinetic genes and 71 SNVs in 35 CNI pharmacodynamic genes (Supplementary Table S1).

Statistical Analyses
Descriptive data are presented as mean ± SD or n (%). The Shapiro-Wilk test was used to assess for normality; non-normally distributed data were log-transformed prior to analysis and back-transformed for presentation. Relationships between demographic and clinical variables (i.e., age at transplant, sex, pre-transplant eGFR, pre-transplant renal dysfunction (eGFR <45 ml/min/1.73 m$^2$; yes/no), heart failure etiology [ischemic cardiomyopathy (CM) vs. other], pre-transplant left ventricular assist device (LVAD; yes/no), pre-transplant hypertension (yes/no), pre-transplant diabetes (yes/no), body mass index (BMI) 1-year post-transplant, transplant era, type of CNI used 1-year post-transplant (i.e., cyclosporine vs. tacrolimus), and angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) prescribed 1-year post-transplant (yes/no)] and the primary and secondary outcomes were assessed using Pearson’s correlation coefficients, with significant covariates ($p < 0.05$) included in the relevant adjusted analyses. Patients were divided into one of three transplant eras, as defined by the most recent International Society for Heart and Lung Transplantation annual report, based on their date of transplant (era 1, 1989–2001; era 2, 2002–2009; era 3, 2010–2016; Khush et al., 2019). To account for potential population stratification, the top four PCs were included in all adjusted analyses performed in the entire cohort. SNVs were analyzed as wild-type (WT) homozygotes vs. variant carriers using a dominant model.

For the primary outcome, univariate analyses were performed using Fisher’s exact tests to identify SNVs associated with renal dysfunction (yes/no). SNVs that were significant after accounting for a false discovery rate (FDR) of 20% were included in a multiple-SNV logistic regression model, adjusting for pertinent covariates and the top four PCs. As exploratory analyses, SNVs suggestively associated with the primary outcome in the univariate analyses [unadjusted $p < 0.05$, but not significant after accounting for multiple comparisons (FDR of 20%)], were investigated in single-SNV logistic regression models, adjusting for relevant covariates and the top four PCs. Univariate analyses to assess the relationship between SNVs and each secondary outcome were performed using $t$-tests. Single-SNV analyses were carried out using linear models and included SNVs suggestively associated [i.e., unadjusted $p < 0.05$ but not significant following adjustment for multiple comparisons (FDR of 20%)] with the secondary outcomes plus relevant covariates and the top four PCs.

For all primary and secondary outcomes, SNV analyses including relevant covariates were also performed in non-Hispanic Americans of European ancestry to assess whether significant and suggestive SNVs remained associated with each outcome in this subgroup. Statistical analyses were performed using R version 3.5.2 (R Foundation for Statistical Computing, Vienna Austria).

RESULTS

Patient Characteristics
Of the 253 participants enrolled in the parent study, 192 participants met the inclusion and exclusion criteria for this 1-year post-transplant analysis. The most common reason participants from the parent study were excluded was the absence of an eGFR measurement prior to transplant ($n = 44$). Characteristics of the 192 participants are shown in Table 1 and described as follows. Most participants were transplanted between May 1989 and August 2016 at the University of Colorado (96.4%). The cohort was primarily of European ancestry (79.2%) and male (77.1%), with a mean ± SD age at transplant of 49 ± 12 years. Tacrolimus (53.1%) was the most frequent CNI used 1-year post-transplant. Pre-transplant hypertension and pre-transplant renal dysfunction were present in 33.3 and 20.3% of patients, respectively. Less than one-third of participants (27.6%) had an LVAD prior to transplant. Approximately two-thirds of patients (63.5%) were prescribed an ACE inhibitor or an ARB 1-year post-transplant.

Renal Dysfunction at 1-Year Post-transplant
Renal dysfunction was present in 28.6% of patients at 1-year post-transplant. Demographic and clinical variables associated with renal dysfunction 1-year post-transplant were the presence
of pre-transplant renal dysfunction ($p = 0.007$), lower pre-transplant eGFR ($p < 0.001$), older age at transplant ($p < 0.001$), cyclosporine use at 1-year post-transplant ($p = 0.003$), and receiving a transplant in an earlier era ($p = 0.021$). Pre-transplant renal dysfunction (yes/no) was selected for inclusion in covariate-adjusted models rather than the continuous measurement of eGFR due to the dichotomous nature of the primary outcome (Oetjens et al., 2014). Transplant era remained significantly associated with renal dysfunction at the 1-year time point after adjusting for type of CNI prescribed ($p = 0.035$). Tacrolimus trough blood levels were significantly lower in patients with vs. without renal dysfunction at 1-year post-transplant ($9.8 \pm 3.6 \text{ ng/mL vs. } 11.7 \pm 3.8 \text{ ng/mL}; p = 0.019$), likely reflecting clinical intervention in response to decreased eGFR. Cyclosporine trough blood levels, tacrolimus total daily dose, and cyclosporine total daily dose did not differ significantly between the two groups at 1-year post-transplant.

Two SNVs [transforming growth factor beta 1 ($\text{TGFB1}$) rs4803455 C $\rightarrow$ A and phospholipase C beta 1 ($\text{PLCB1}$) rs170549 G $\rightarrow$ A] were significantly associated with renal dysfunction 1-year post-transplant in the univariate analyses after adjusting for an FDR of 20% (unadjusted $p = 0.004$ for both SNVs). Renal dysfunction was present in 43% of participants with the $\text{TGFB1}$ rs4803455 C/C genotype vs. 22% of variant A.

### Table 1: Participant demographic and clinical characteristics.

| Characteristic                        | Entire cohort ($N = 192$) | No renal dysfunction at 1-year post-transplant ($N = 137$) | Renal dysfunction* at 1-year post-transplant ($N = 55$) | $p$          |
|--------------------------------------|---------------------------|----------------------------------------------------------|------------------------------------------------------|-------------|
|                                      |                           |                                                          |                                                      |             |
| Sex (male)                           | 148 (77.1%)               | 110 (80.3%)                                              | 38 (69.1%)                                           | 0.128       |
| Age at transplant (years)            | 49 ± 12                   | 47 ± 13                                                  | 55 ± 9                                               | $<0.001$    |
| Race                                 |                           |                                                          |                                                      |             |
| European American                    | 152 (79.2%)               | 106 (77.4%)                                              | 46 (83.6%)                                           | 0.222       |
| African American                     | 17 (8.9%)                 | 15 (10.9%)                                               | 2 (3.6%)                                             |             |
| Asian                                | 7 (3.6%)                  | 6 (4.4%)                                                 | 1 (1.8%)                                             |             |
| Other                                 | 18 (8.3%)                 | 10 (7.3%)                                                | 6 (10.9%)                                            |             |
| Ethnicity                            |                           |                                                          |                                                      | 1.000       |
| Non-Hispanic                         | 172 (89.6%)               | 123 (89.6%)                                              | 49 (89.1%)                                           |             |
| Hispanic                             | 20 (10.4%)                | 14 (10.2%)                                               | 6 (10.9%)                                            |             |
| Reason for transplant                |                           |                                                          |                                                      | 0.957       |
| Nonischemic CM                       | 91 (47.4%)                | 67 (48.9%)                                               | 24 (43.6%)                                           |             |
| Ischemic CM                          | 64 (33.3%)                | 44 (32.1%)                                               | 20 (36.4%)                                           |             |
| Valvular CM                          | 9 (4.7%)                  | 6 (4.4%)                                                 | 3 (5.5%)                                             |             |
| Mixed etiology                       | 8 (4.2%)                  | 6 (4.4%)                                                 | 2 (3.6%)                                             |             |
| Congenital CM                        | 8 (4.2%)                  | 5 (3.6%)                                                 | 3 (5.5%)                                             |             |
| Other                                 | 12 (6.3%)                 | 9 (6.6%)                                                 | 3 (5.5%)                                             |             |
| Pre-transplant hypertension          | 64 (33.3%)                | 47 (34.3%)                                               | 17 (30.9%)                                           | 0.736       |
| Pre-transplant diabetes              | 25 (13.0%)                | 16 (11.7%)                                               | 9 (16.4%)                                            | 0.477       |
| Pre-transplant eGFR (ml/min/1.73 m²) | 66 ± 27                   | 71 ± 28                                                  | 51 ± 16                                              | $<0.001$    |
| Pre-transplant renal dysfunction*     | 39 (20.3%)                | 21 (15.3%)                                               | 18 (32.7%)                                           | 0.010       |
| Pre-transplant LVAD                  | 53 (27.6%)                | 39 (28.5%)                                               | 14 (25.5%)                                           | 0.724       |
| Body mass index (kg/m²)              | 27.0 ± 4.8                | 26.5 ± 4.6                                               | 28.1 ± 5.3                                           | 0.056       |
| eGFR 1-year post-transplant (ml/min/1.73 m²) | 55 ± 20                | 63 ± 19                                                  | 37 ± 6                                               | $<0.001$    |
| Change in eGFR (ml/min/1.73 m²)³     | $-10 ± 21$                | $-8 ± 23$                                                | $-14 ± 15$                                           | 0.037       |
| Calcineurin inhibitor*               | 102 (53.1%)               | 82 (59.9%)                                               | 20 (36.4%)                                           | 0.004       |
| Tacrolimus                           | 90 (46.9%)                | 55 (40.1%)                                               | 35 (63.6%)                                           |             |
| Tacrolimus total daily dose (mg/day)² | 6.3 ± 4.8                | 6.5 ± 5.1                                                | 5.3 ± 3.2                                            | 0.291       |
| Tacrolimus trough level (ng/ml)²     | 11.4 ± 3.8                | 11.7 ± 3.8                                               | 9.8 ± 3.6                                            | 0.019       |
| Cyclosporine total daily dose (mg/day)² | 278 ± 96                 | 284 ± 92                                                 | 269 ± 102                                            | 0.339       |
| Cyclosporine trough level (ng/ml)²   | 238 ± 101                 | 242 ± 109                                                | 232 ± 89                                             | 0.630       |
| Antiproliferative agent*             | 153 (79.7%)               | 115 (83.9%)                                              | 38 (69.1%)                                           | 0.111       |
| Mycophenolate                        | 28 (14.6%)                | 14 (10.2%)                                               | 14 (25.5%)                                           |             |
| Azathioprine                         | 11 (5.7%)                 | 8 (5.8%)                                                 | 3 (5.5%)                                             |             |
| None                                 | 122 (63.5%)               | 86 (64.2%)                                               | 34 (61.8%)                                           | 0.744       |
| ACE inhibitor/ARB²                   | 54 (28.1%)                | 35 (25.5%)                                               | 25 (45.5%)                                           | 0.031       |
| Transplant era                       |                           |                                                          |                                                      |             |
| Era 1: 1989–2001                     | 60 (31.3%)                | 35 (25.5%)                                               | 25 (45.5%)                                           |             |
| Era 2: 2002–2009                     | 58 (30.2%)                | 49 (32.8%)                                               | 13 (23.6%)                                           |             |
| Era 3: 2010–2016                     | 74 (38.5%)                | 57 (41.8%)                                               | 17 (30.9%)                                           |             |

Data are presented as mean ± SD or N (%). Percentages may not equal 100% due to rounding. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CM, cardiomyopathy; eGFR, estimated glomerular filtration rate; and LVAD, left ventricular assist device.

1For FDR < 0.05.
2eGFR < 45 ml/min/1.73 m² calculated using the Modification of Diet in Renal Disease (MDRD) formula.
3Includes n = 15 Hispanics and n = 1 American Indian.
4At 1-year clinic visit.

Change in eGFR from pre-transplant to 1-year post-transplant.

Calcineurin inhibitor is a drug used to prevent organ rejection after transplant surgery.

Antiproliferative agent includes drugs like Mycophenolate, which is also used in transplant patients.

The table highlights the differences in participant demographics and clinical characteristics, focusing on factors like post-transplant renal dysfunction, eGFR, and other covariates.
carriers, and 20% of participants with the PLCB1 rs170549 G/G genotype vs. 39% of variant A carriers. TGFBI rs4803455 and PLCB1 rs170549 remained significantly associated with the primary outcome in a multiple-SNV covariate-adjusted logistic regression model (Table 2). Specifically, TGFBI rs4803455 variant A carriers had lower odds of renal dysfunction when compared to participants with the C/C genotype [odds ratio (OR) 0.28; 95% CI 0.12–0.62; p = 0.002]. In contrast, PLCB1 rs170549 variant A allele carriers had higher odds of renal dysfunction than G/G homozygotes (OR 2.66; 95% CI 1.21–5.84; p = 0.015). Additionally, both SNVs were significantly associated with pre-transplant renal dysfunction, with this morbidity occurring in 30% of participants with the TGFBI rs4803455 C/C genotype vs. 16% of variant A carriers (p = 0.018), and 12% of participants with the PLCB1 rs170549 G/G genotype vs. 30% of variant A carriers (p = 0.002). When limiting the multiple-SNV covariate-adjusted analysis to non-Hispanic Americans of European ancestry, both TGFBI rs4803455 C > A (OR 0.39; 95% CI 0.17–0.90; p = 0.027) and PLCB1 rs170549 G > A (OR 2.52; 95% CI 1.10–5.77; p = 0.029) remained significantly associated with the outcome (Supplementary Table S2).

Six SNVs in the univariate analyses were suggestively associated with renal dysfunction 1-year post-transplant but were not significant after accounting for an FDR of 20% (Table 3). As an exploratory analysis, each SNV was evaluated in a single-SNV logistic regression model, adjusting for pre-transplant renal dysfunction, age at transplant, type of CNI prescribed at 1-year post-transplant, transplant era, and the top four PCs. Five SNVs [calcium voltage-gated channel subunit alpha1 D (CACNA1D) rs893365 C > T, protein phosphatase 3 catalytic subunit gamma (PPP3CC) rs10108011 A > G, PPP3CC rs2461494 A > G, protein kinase AMP-activated non-catalytic subunit gamma 2 (PRKAG2) rs7805747 G > A, and nuclear receptor subfamily 3 group C member 2 (NR3C2) rs1490453 G > A] remained suggestively associated with the primary outcome in the single-SNV covariate-adjusted models. The odds of renal dysfunction were higher in variant carriers of PPP3CC rs10108011, PPP3CC rs2461494, and PRKAG2 rs7805747, whereas the odds of renal dysfunction were lower in variant carriers of CACNA1D rs893365 and NR3C2 rs1490453. When these five SNVs were evaluated in non-Hispanic Americans of European ancestry, only CACNA1D rs893365 and PRKAG2 rs7805747 continued to be associated with lower and higher odds of renal dysfunction 1-year post-transplant, respectively, after adjusting for covariates (Supplementary Table S3).

**eGFR 1-Year Post-transplant**

A histogram of the eGFR measurements closest to the 1-year transplant anniversary is shown in Figure 1. The mean ± SD time from the 1-year anniversary to the eGFR measurement was 10 ± 9 days. The mean eGFR 1-year post-transplant was 55 ± 20 ml/min/1.73 m². Demographic and clinical variables associated with lower eGFR 1-year post-transplant were female sex (p = 0.018), presence of pre-transplant renal dysfunction (p < 0.001), lower pre-transplant eGFR (p < 0.001), older age at transplant (p < 0.001), cyclosporine use at 1-year post-transplant (p = 0.001), and higher BMI at 1-year post-transplant (p = 0.002). The measurement of pre-transplant eGFR was included as a covariate in adjusted analyses, as the outcome (i.e., eGFR 1-year post-transplant) was a continuous variable.
Five SNVs were suggestively associated with eGFR 1-year post-transplant ($p < 0.05$; Table 4), but they did not withstand correction for multiple testing (FDR of 20%). As an exploratory analysis, each SNV was evaluated in a single-SNV adjusted linear regression model, adjusting for the demographic and clinical variables above. Two SNVs in the protein phosphatase 3 regulatory subunit B alpha (PPP3R1) gene, rs875 A > G and rs12465425 T > G, remained suggestively associated with the outcome in single-SNV adjusted models, with variant G allele carriers having higher eGFR 1-year post-transplant compared to WT homozygotes for both SNVs. Neither of these two PPP3R1 SNVs were suggestively associated with eGFR 1-year post-transplant in the single-SNV adjusted models when limiting the analysis to non-Hispanic Americans of European ancestry (Supplementary Table S4).

**Change in eGFR**

The mean change in eGFR from pre-transplant to 1-year post-transplant was $-10 \pm 21$ ml/min/1.73 m$^2$ (Figure 2). Demographic and clinical variables associated with a greater decrease in eGFR and included in the multivariable models were presence of a LVAD prior to transplant ($p < 0.001$), absence of pre-transplant diabetes ($p = 0.033$), younger age at transplant ($p < 0.001$), and not being prescribed an ACE inhibitor or ARB 1-year post-transplant ($p = 0.013$). No SNVs were significantly associated with change in eGFR.

---

**TABLE 4** Unadjusted and adjusted single-SNV analyses for SNVs suggestively associated with eGFR at 1-year post-transplant.

| Gene name | rs number | Chromosome | Alleles$^b$ | MAF (%) | Unadjusted value of $p$ | Adjusted eGFR$^c$ (95% CI) WT homozygotes | Adjusted eGFR$^c$ (95% CI) variant carriers | Adjusted$^d$ value of $p$ |
|-----------|-----------|------------|------------|---------|------------------------|---------------------------------------------|---------------------------------------------|-------------------------|
| PPP3R1$^a$ | rs875     | 2          | A > G      | 32      | 0.017                  | 49 (46–51)                                  | 54 (51–57)                                  | 0.009                   |
| PPP3R1$^a$ | rs12465425| 2          | T > G      | 32      | 0.013                  | 49 (47–52)                                  | 54 (51–57)                                  | 0.010                   |
| PPP3CC    | rs10109011| 8          | A > G      | 42      | 0.016                  | 54 (50–57)                                  | 50 (48–53)                                  | 0.142                   |
| PRKAG2    | rs7805747 | 7          | G > A      | 24      | 0.012                  | 52 (50–55)                                  | 50 (47–53)                                  | 0.219                   |
| PLCB1     | rs170549  | 20         | G > A      | 28      | 0.025                  | 51 (49–55)                                  | 51 (48–54)                                  | 0.808                   |

*eGFR, estimated glomerular filtration rate; MAF, minor allele frequency; PLCB1, phospholipase C beta 1; PPP3CC, protein phosphatase 3 catalytic subunit gamma; PPP3R1, protein phosphatase 3 regulatory subunit B alpha; PRKAG2, protein kinase AMP-activated non-catalytic subunit gamma 2; SNV, single nucleotide variant; and WT, wild-type.

$^a$Calculated using the MDRD formula.

$^b$Major > minor alleles, respectively.

$^c$Models adjusted for sex, pre-transplant eGFR, age at transplant, cyclosporine use at 1-year post-transplant, body mass index (BMI) at 1-year post-transplant, and the top four PCs.

$^d$PPP3R1 SNVs are correlated ($r^2 = 0.91$).
using an FDR of 20%. Four SNVs were suggestively associated with the outcome in univariate analyses ($p < 0.05$; Table 5) and were included in exploratory single-SNV multivariable models, adjusting for the covariates listed above and the top four PCs. Two SNVs (rs1800255 G > A and rs1878201 A > G) in the collagen type III alpha 1 chain (COL3A1) gene remained suggestively associated with change in eGFR from pre-transplant to 1-year post-transplant in the single-SNV adjusted models. Variant carriers had greater decline in eGFR in the 1st-year post-transplant vs. WT homozygotes for both SNVs. COL3A1 rs1800255 and rs1878201 were no longer suggestively associated with the outcome in single-SNV adjusted analyses in non-Hispanic Americans of European ancestry (Supplementary Table S5).

**DISCUSSION**

In this study, we utilized a candidate gene approach to examine the association between 93 SNVs in CNI pharmacokinetic and pharmacodynamic genes and renal impairment following heart transplantation. Our study, in which the majority of patients were prescribed tacrolimus at the 1-year time point, is one of the largest and most comprehensive to date in this population. Two SNVs, TGFBI rs4803455 and PLCB1 rs170549, were associated with renal dysfunction 1-year post-transplant after accounting for an FDR of 20%. TGFBI-1, encoded by TGFBI, is a cytokine involved in the development of fibrosis, a key histological feature of chronic CNI exposure (Randhawa et al., 1993; Border and Noble, 1994). The expression
of this important protein is modulated by the cell signaling enzyme, PLCB1 (Slattery et al., 2005).

We found variant A allele carriers of rs4803455 C > A, located in intron 2 of TGBF1, had lower odds of renal dysfunction compared to C/C homozygotes. TGBF1-1 has been associated with increased fibrosis in multiple tissues, including the kidneys (Border and Noble, 1994). Importantly, two of the hallmarks of chronic renal dysfunction after transplantation are interstitial fibrosis and tubular atrophy (Myers et al., 1984; Randhawa et al., 1993). Intrarenal TGFβ1 expression has been shown to increase following administration of tacrolimus and cyclosporine (Khanna et al., 2002; Roos-van Groningen et al., 2006). Lachance et al. previously reported an association between TGBF1 rs4803455 and eGFR in heart transplant recipients, of whom 21% were receiving tacrolimus and the average time post-transplant was 4.3 years (Lachance et al., 2012). However, that study did not describe which allele conveyed worse renal function, nor did it provide an estimate of the strength of the association. In non-transplant populations, variant A allele carriers of rs4803455 have been reported to have reduced risk of myopia, asthma, the formation of carotid plaque, breast cancer, and endometrial cancer (Zha et al., 2009; Wu et al., 2010; Deng et al., 2011; Boone et al., 2013; Yang et al., 2016). To date, rs4803455 has not been directly shown to influence TGBF1 gene expression or protein function. Due to its location in intron 2, further investigation is warranted to identify if a functional variant in linkage disequilibrium with rs4803455 is driving the observed associations.

Other studies have reported an association between the TGBF1 missense variant, Leu10Pro (L10P), and renal function in heart transplant recipients (Baan et al., 2000; Lacha et al., 2001; van de Wetering et al., 2006). Codon 10 proline carriers had a higher risk of renal dysfunction in patients taking CNIs compared to leucine/leucine patients in two studies, whereas Lacha et al. reported worse progression of renal dysfunction in leucine carriers (Baan et al., 2000; Lacha et al., 2001; van de Wetering et al., 2006). We found no association between L10P and renal function outcomes at 1-year post-transplant in our cohort. Our results agree with Klaue et al. (2008) and Lachance et al. (2012) both of whom found no association between L10P and renal function in heart transplant recipients. Possible reasons for the discrepant results between studies include the variable post-transplant time points analyzed and differing definitions of renal dysfunction. Nonetheless, our results, in combination with previous findings, suggest that SNVs in TGBF1 may play a role in the development of renal dysfunction following heart transplantation.

We also found that carriers of the intronic PLCB1 rs170549 variant A allele had higher odds of renal dysfunction when compared to individuals with the G/G genotype. PLCB1 catalyzes the formation of diacylglycerol and is expressed in multiple tissues, including vascular smooth muscle cells (Schelling et al., 1997; Hisatsune et al., 2005). In turn, diacylglycerol activates protein kinase C, which regulates a variety of cellular targets via phosphorylation (Nishizuka, 1988). Protein kinase C has been shown to modulate cyclosporine-induced up-regulation of TGBF-1 and inhibition of endothelial nitric oxide synthase by tacrolimus (Slattery et al., 2005; Chiasson et al., 2011). Furthermore, PLCB1 rs170549 has previously been associated with eGFR in adult heart transplant recipients, although the study did not describe which allele was associated with worse renal function, nor the magnitude of the association (Lachance et al., 2012). Given that rs170549 is located in an intron, it may be in linkage disequilibrium with another functional variant in PLCB1, which could influence its protein structure and/or expression. Thus, additional studies are needed to elucidate the mechanism by which PLCB1 rs170549, or a functional SNV linked with this intronic variant, influences the development of renal dysfunction in heart transplant recipients receiving CNIs.

In exploratory analyses, we found carriers of the CACNA1D rs893365 variant T allele had lower odds of renal dysfunction 1-year post-transplant. CACNA1D encodes a subunit of the calcium channel, Ca1.3, which plays an important role in the production and secretion of aldosterone from the adrenal cortex (Yang et al., 2020). Aldosterone increases sodium and fluid retention which, in turn, results in higher blood pressure as part of renin-angiotensin-aldosterone system (RAS) activation. RAS activation leads to vasoconstriction of renal afferent and efferent arterioles, changes which are also observed following CNI treatment (Kaye et al., 1993; Textor et al., 1995; Mennuni et al., 2014). Another intronic variant in CACNA1D, rs9810888, has previously been associated with the presence of hypertension in non-transplanted adults (Lu et al., 2015). As such, genetic variation in CACNA1D may increase the odds of developing hypertension, a condition that contributes to the occurrence of renal dysfunction after heart transplantation and which is exacerbated by CNI use (Lindendfeld et al., 2004). We also found PRKAG2 rs7805747 variant A allele has been associated with higher odds of renal impairment 1-year after transplant than G/G homozygotes. PRKAG2 encodes the gamma-2 subunit of AMP-activated protein kinase, an enzyme that regulates metabolism during cellular stress (Hardie et al., 1998). Furthermore, AMP-activated protein kinase may protect against the development of tubulointerstitial renal fibrosis, a common histological finding in patients treated with CNIs, through the inhibition TGBF-1 (Naessen et al., 2009; Lee et al., 2013). In silico data suggest PRKAG2 rs7805747 could affect the binding of transcription factors, such as hepatocyte nuclear factor 4 alpha, to PRKAG2 (Wang et al., 2018). Additionally, the PRKAG2 rs7805747 variant A allele has been associated with higher odds of renal dysfunction in genome-wide association studies in non-transplant populations (Kottgen et al., 2010; Pattaro et al., 2016). Given the exploratory nature of our analyses, the lack of in vitro data describing the functional significance of CACNA1D rs893365 and PRKAG2 rs7805747, and the intronic location of both variants, further studies are necessary to determine how these SNVs, or linked functional variants, impact renal function in heart transplant recipients prescribed CNIs.

There are limitations to our study that deserve to be acknowledged. First, there was a broad range of dates of transplant in our cohort (1989–2016). Patient care during
this period has changed, and some of these changes might have influenced renal dysfunction (e.g., type of CNI used, CNI goal ranges). Second, it is likely that survival bias is present, with some patients with renal dysfunction dying prior to study enrollment. Furthermore, we did not include patients with severe renal impairment whose CNI was discontinued in favor of an mTOR inhibitor (i.e., sirolimus or everolimus), which may also bias our results. Third, multiple suggestive SNVs from the whole cohort were not associated with the primary and secondary outcomes when the analysis was limited to non-Hispanic Americans of European ancestry. While this may be due, in part, to a reduction in power, we cannot exclude the possibility that population stratification may have impacted these findings. Fourth, the functional effects of many of the significant and suggestive SNVs have not been reported in the literature. Future studies should focus on replicating these findings and determining the mechanistic underpinnings of their effects. Fifth, the two SNVs significantly associated with renal dysfunction 1-year post-transplant in our cohort were also associated with pre-transplant renal dysfunction. While these SNVs continued to be associated with the primary outcome after accounting for pre-transplant renal impairment in multi-SNV adjusted models, it is possible that the effects of these variants on renal function post-transplant may exist independent of CNI exposure. Finally, we used a single eGFR measurement in our primary and secondary outcomes. Although this is a common approach to assess renal function post-transplant, it may not capture other acute processes that may have occurred around that time point (e.g., acute kidney injury, dehydration; Sanchez-Lazaro et al., 2015; Asleh et al., 2018).

In conclusion, we provide additional evidence that SNVs in the pro-fibrotic TGFβ1 and cell signaling PLCB1 genes may play a role in the development of renal dysfunction in adult heart transplant recipients taking CNIs. Novel genetic markers, such as TGFβ1 rs4803455 and PLCB1 rs170549, may serve as tools that clinicians can utilize to assess a patient’s risk of CNI-associated renal dysfunction following heart transplantation, thereby improving clinical care and advancing precision medicine in this population.

**DATA AVAILABILITY STATEMENT**

The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Colorado Multiple Institutional Review Board. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

CA conceptualized the study idea. KO, CA, and KD designed the study and collected and analyzed the data. LS and NR aided in data analysis. AA, JL, and RP were involved in patient recruitment and provided clinical input. KO and CA wrote the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was funded by a grant from the American Heart Association (12GRNT12040211). This project/publication was supported by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535 and by NIH/NCATS Colorado CTSA Grant Number TL1 TR002533. Contents were the authors’ sole responsibility and do not necessarily represent official NIH views.

**ACKNOWLEDGMENTS**

We would like to thank the patients who participated in this study. We would also like to thank the Colorado Anschutz Research Genetics Organization for genotyping the samples. Results from this study were previously published, in part, as an abstract in the *J. Heart Lung Transplant*. 2020; 39:S94.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.658983/full#supplementary-material

**REFERENCES**

1000 Genomes Project Consortium (2015). A global reference for human genetic variation. *Nature* 526, 68–74. doi: 10.1038/nature15393
Alba, A. C., Bain, E., Ng, N., Stein, M., O’Brien, K., Foroutan, E., et al. (2016). Complications after heart transplantation: hope for the best, but prepare for the worst. *Int. J. Transplant. Res. Med*. 2, 1–11. doi: 10.23937/2572-4045.1510022
Asleh, R., Snipelsky, D., Hathcock, M., Kremers, W., Liu, D., Batzler, A., et al. (2018). Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients. *Clin. Transpl*. 32:e13395. doi: 10.1111/ctr.13395

Baan, C. C., Balk, A. H., Holweg, C. T., van Riemstjik, I. C., Maat, L. P., Vantrimponp, P. J., et al. (2000). Renal failure after clinical heart transplantation is associated with the TGF-β1 codon 10 gene polymorphism. *J. Heart Lung Transplant*. 19, 866–872. doi: 10.1016/S1053-2498(00)00155-8
Boone, S. D., Baumgartner, K. B., Baumgartner, R. N., Connor, A. E., Pinkston, C. M., John, E. M., et al. (2013). Associations between genetic variants in the TGF-beta signaling pathway and breast cancer risk among Hispanic and non-Hispanic white women. *Breast Cancer Res. Treat*. 141, 287–297. doi: 10.1007/s10549-013-2690-z
Border, W. A., and Noble, N. A. (1994). Transforming growth factor beta in tissue fibrosis. *N. Engl. J. Med*. 331, 1286–1292. doi: 10.1056/NEJM19941103311907
Lee, J. H., Kim, J. H., Kim, J. S., Chang, J. W., Kim, S. B., Park, J. S., et al. (2013). AMP-activated protein kinase inhibits TGF-beta-, angiotensin II-, aldosterone-, high glucose-, and albumin-induced epithelial-mesenchymal transition. *Am. J. Physiol. Renal Physiol.* 304, F686–F697. doi:10.1152/ajprenal.00483.2012

Lemk, J., Miller, G. G., Shakar, S. F., Zobl, R., Lowes, B. D., Wolfel, E., et al. (2004). Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. *Circulation* 110, 3858–3865. doi:10.1161/01.CIR.0000150332.42276.69

Lu, X., Wang, L., Lin, X., Huang, J., Charles, G. C., He, M., et al. (2015). Genome-wide association study in Chinese identifies novel loci for blood pressure and hypertension. *Hum. Mol. Genet.* 24, 865–874. doi:10.1093/hmg/ddu478

Mathias, R. A., Taub, M. A., Gignoux, C. R., Fu, W., Masharorof, S., O'Connor, T. D., et al. (2016). A continuum of admixture in the western hemisphere revealed by the African diaspora genome. *Nat. Commun.* 7, 12252. doi:10.1038/ncomms12252

Matise, T. C., Ambite, J. L., Buyse, S., Carlson, C. S., Cole, S. A., Crawford, D. C., et al. (2011). The next PAGE in understanding complex traits: design for the analysis of population architecture using genetics and epidemiology (PAGE study). *Am. J. Epidemiol.* 174, 849–859. doi:10.1093/aje/kwr160

McCarthy, S., Das, S., Kretzschmar, W., Delanoue, O., Wood, A. R., Teumer, A., et al. (2016). A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* 48, 1279–1283. doi:10.1038/ng.3643

Mennuni, S., Rubattu, S., Pierelli, G., Tocci, G., Fofi, C., and Volpe, M. (2014). Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. *J. Hum. Hypertens.* 28, 74–79. doi:10.1038/jhh.2013.55

Myers, B. D., Ross, J., Newton, L., Luetscher, J., and Perlofth, M. (1984). Cyclosporine-associated chronic nephropathy. *N. Engl. J. Med.* 311, 699–705. doi:10.1056/NEJM198409133111103

Naesens, M., Kuypers, D. R., and Sarwal, M. (2009). Calcineurin inhibitor nephrotoxicity. *Clin. J. Am. Soc. Nephrol.* 4, 481–508. doi:10.2215/CJN.04800098 National Kidney Foundation (2002). *KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis.* 39, S1–S266.

Navarro-Manchon, J., Martinez-Dolz, L., Almenar Bonet, L., Sánchez-Lázaro, I., Raso Raso, R., Grima, E., et al. (2010). Predictors of renal dysfunction at 1 year in heart transplant patients. *Transplantation* 89, 977–982. doi:10.1097/TP0b013e3181c80d24

Nishizuka, Y. (1988). The molecular heterogeneity of protein kinase C and its implications for cellular regulation. *Nature* 334, 661–665. doi:10.1038/334661a0

Oetjens, M., Bush, W. S., Birdwell, K. A., Dills, H. B., Bowton, E. A., Denny, J. C., et al. (2014). Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients. *Pulm. Soc. Biocomput.* 235–264. doi:10.2215/19978914583220_0023

Ojo, A. O. (2007). Renal disease in recipients of nonrenal solid organ transplantation. *Transplant. Rev.* 27, 498–507. doi:10.1016/j.transrv.2007.03.010

Ojo, A. O., Held, P. J., Port, F. E., Wolfe, R. A., Leichtman, A. B., Young, E. W., et al. (2003). Chronic renal failure after transplantation of a nonrenal organ. *N. Engl. J. Med.* 349, 931–940. doi:10.1056/NEJMoa021744

Pattaro, C., Teumer, A., Gorski, M., Chu, A. Y., Li, M., Mijatovic, V., et al. (2016). Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nat. Commun.* 7:10023. doi:10.1038/ncomms10023

Randhawa, P. S., Shapiro, R., Jordan, M. L., Starzl, T. E., and Demetris, A. J. (1993). The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. *Am. J. Surg. Pathol.* 17, 60–68. doi:10.1097/00000478-199301000-00007

Rodon, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., et al. (2019). Pharmacogenomics. *Lancet* 394, 521–532. doi:10.1016/S0140-6736(19)31276-0

Roos-van Groningen, M. C., Scholten, E. M., Leelved, P. M., Rovshen, A. T., Baelder, H. E., Baijema, I. M., et al. (2006). Molecular comparison of calcineurin inhibitor-induced fibrogenic responses in protocol renal transplant biopsies. *J. Am. Soc. Nephrol.* 17, 881–888. doi:10.1097/01jas.2005080891

Sánchez-Lázaro, I., Herrero, M. J., Jordan-De Luna, C., Bosó, V., Almenar, L., Rojas, L., et al. (2015). Association of SNPs with the efficacy and safety of immunosuppressant therapy after heart transplantation. *Pharmacogenomics* 16, 971–979. doi:10.2217/pgs.15.39
Schelling, J. R., Nkemere, N., Konieczkowski, M., Martin, K. A., and Dubyak, G. R. (1997). Angiotensin II activates the beta 1 isoform of phospholipase C in vascular smooth muscle cells. Am. J. Phys. 272, C1558–C1566. doi: 10.1152/ajpcell.1997.272.5.C1558

Slattery, C., Campbell, E., McMorrow, T., and Ryan, M. P. (2005). Cyclosporine A-induced renal fibrosis: a role for epithelial-mesenchymal transition. Am. J. Pathol. 167, 395–407. doi: 10.1016/S0002-9440(10)62984-7

Smith, H. E., Jones, J. P. 3rd, Kalhorn, T. F., Farin, F. M., Stapleton, P. L., Davis, C. L., et al. (2008). Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet. Genomics 18, 943–953. doi: 10.1097/FPC.0b013e328301e16

Textor, S. C., Burnett, J. C. Jr., Romero, J. C., Canzanello, V. J., Taler, S. J., Wiesner, R., et al. (1995). Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 47, 1426–1433. doi: 10.1038/ki.1995.200

van de Wetering, J., Weimar, C. H., Balk, A. H., Roodnat, J. I., Holweg, C. T., Baan, C. C., et al. (2006). The impact of transforming growth factor-beta1 gene polymorphism on end-stage renal failure after heart transplantation. Transplantation 82, 1744–1748. doi: 10.1097/TP.0000250360.78553.5e

Wang, E., Zhao, H., Zhao, D., Li, L., and Du, L. (2018). Functional prediction of chronic kidney disease susceptibility gene PRKAG2 by comprehensively bioinformatics analysis. Front. Genet. 9:573. doi: 10.3389/fgene.2018.00573

Wilkinson, A. H., and Cohen, D. J. (1999). Renal failure in the recipients of nonrenal solid organ transplants. J. Am. Soc. Nephrol. 10, 1136–1144.

Wu, H., Romieu, I., Shi, M., Hancock, D. B., Li, H., Sienna-Monge, J.-J., et al. (2010). Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans. J. Allergy Clin. Immunol. 125, 321.e13–327.e13. doi: 10.1016/j.jaci.2009.09.007

Yang, T., He, M., Zhang, H., Barrett, P. Q., and Hu, C. (2020). L- and T-type calcium channels control aldosterone production from human adrenals. J. Endocrinol. 244, 237–247. doi: 10.1530/JOE-19-0259

Yang, L., Wang, Y. J., Zheng, L. Y., Jia, Y.-M., Chen, Y.-L., Cheny, L., et al. (2016). Genetic polymorphisms of TGFβ1, TGFβR1, SNAI1 and TWIST1 are associated with endometrial cancer susceptibility in Chinese han women. PLoS One 11:e0155270. doi: 10.1371/journal.pone.0169039

Zalawadiya, S., Fudim, M., Bhat, G., Cotts, W., and Lindenfeld, J. (2017). Extracorporeal membrane oxygenation support and post-heart transplant outcomes among United States adults. J. Heart Lung Transplant. 36, 77–81. doi: 10.1016/j.healun.2016.10.008

Zha, Y., Leung, K. H., Lo, K. K., Fung, W. F., Ng, P. W., Shi, M.-G., et al. (2009). TGFβ1 as a susceptibility gene for high myopia: a replication study with new findings. Arch. Ophthalmol. 127, 541–548. doi: 10.1001/ archophthalmol.2008.623

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Oreschak, Saba, Rafaels, Ambardekar, Deininger, Page, Lindenfeld and Aquilante. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.